Gemphire Therapeutics to Participate in the Canaccord Genuity Rare Disease and Biopharma 1 on 1 Day
Thursday, February 2, 2017
Posted by: Kate Oesterle
Gemphire Therapeutics to Participate in the Canaccord Genuity Rare Disease and Biopharma 1 on 1 Day and the RBC Capital Markets Global Healthcare Conference
LIVONIA, Mich., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia and NAFLD/NASH, today announced that its senior management team will participate in two investor conferences in New York City during the month of February.
Mina Sooch, President and CEO, will be attending the Canaccord Genuity Rare Disease and Biopharma 1x1 Day and will be available to meet investors on Tuesday, February 7 at the InterContinental Barclay, New York. In the ultra-orphan homozygous familial hypercholesterolemia (HoFH) patient population, Gemphire recently announced interim data on the LDL-C primary endpoint from the ongoing open label Phase 2b COBALT-1 trial. The data, on two genetically confirmed HoFH patients, showed that gemcabene 600mg decreased mean LDL-C by 28% on top of maximum statin lipid-lowering therapy. The slide presentation used during the Canaccord Genuity conference will be posted to the Gemphire corporate website on February 7.
Ms. Sooch will also be presenting at the RBC Capital Markets Global Healthcare Conference on Thursday, February 23, at 8.30am Eastern Time at the New York Palace Hotel. The presentation will be in a “Fireside Chat” format. An audio webcast of the RBC event will be broadcast simultaneously on the News & Events section of the Gemphire website for all interested parties, and will be archived and available for 90 days.
Read full article here.